-
Other CNS diseases
- RETT Syndrome
Rett syndrome is a rare, severe genetic neurodevelopmental disorder that affects approximately 1 in 10.000 females. The disease is most commonly caused by spontaneous mutations in the MeCP2 gene, located on the X chromosome. The resulting reduced function of MeCP2 protein affects the normal development and function of brain cells and is associated with impaired neuronal maturation and communication, mitochondrial dysfunction, and oxidative stress.
Symptoms typically begin between 6 and 18 months of age and become more noticeable with regression of achieved developmental milestones. Common features include loss of purposeful hand use and speech, movement difficulties as well as seizures, breathing irregularities, scoliosis, and sleep disturbances.Life expectancy may be reduced, although many individuals live into their 50s and beyond. There is currently no cure for Rett. Treatment options remain limited, with trofinetide being the only approved therapy for Rett syndrome in the US and EU.
Orphan neurodevelopmental disorder
De novo mutations in the MECP2 gene on the X chromosome
Prevalence 1 in 10,000 females
MECP2 deficiency impairs mitochondrial bioenergetics and structure
Main symptoms: Neurodevelopmental regression, loss of motor and communication skills, seizures and epilepsy, breathing abnormalities, severe autism-like symptoms
Disease onset between 6 and 18 month of age
FRDA
Friedreich's Ataxia (FRDA) is a rare genetic disease characterized by loss of coordination and muscle strength resulting from the degeneration of nerve tissue in the spinal cord and damage of the peripheral nerves that control muscle movement. Symptoms range from the inability to coordinate movements to gait instability with imbalance, muscle weakness and tremors. Patients lose their ability to stand, sit and walk within 10 – 15 years of onset. FRDA reduces life expectancy and becomes fatal, mainly due to cardiac failure. Friedreich's Ataxia is caused by a genetic defect which affects male and female children and is inherited as a recessive trait. Deficient expression of the mitochondrial protein, frataxin, is the primary cause of FRDA, which leads to adverse alterations in whole cell and mitochondrial iron metabolism causing iron accumulation, mitochondrial dysfunction and oxidative damage. The prevalence of FRDA is approximately 1 in 40,000 people. There is currently no known cure available and patients manage their disease with symptomatic treatment only.
Orphan neurodegenerative mitochondrial disease
GAA repeats in the frataxin gene
Prevalence of 1/40,000
Reduced frataxin levels leading to mitochondrial dysfunction
Main symptoms: Ataxia, Cardiomyopathy Diabetes mellitus
Early-intermediate onset between 5 and 24 years of age
